Videx EC is an oral formulation of the nucleoside reverse transcriptase inhibitor used in the treatment of hiv infection. The drug is chemically identified as dexoxivudine ethyl ester, a prodrug that enhances intracellular delivery of the active metabolite. Once absorbed, the ethyl ester moiety is hydrolyzed to release oxivudine, which is phosphorylated to its triphosphate form inside host cells. The triphosphate analogue mimics the natural deoxyguanosine monophosphate and acts as a substrate for viral reverse transcriptase. Incorporation of the triphosphate into the viral dna chain terminates elongation, preventing further synthesis of viral genetic material. By selectively inhibiting hiv reverse transcriptase, Videx EC reduces viral replication in patients with compensated liver disease. The phosphorylated form persists in infected lymphocytes, leading to sustained antiviral activity. Clinical studies have demonstrated that the medication provides durable suppression of plasma viral load when used as part of a combination regimen.

Videx EC is an oral formulation of the antiviral medication didanosine used to treat hiv infection. It functions as a nucleoside reverse transcriptase inhibitor that interferes with the replication of the virus. The drug is converted intracellularly to the active triphosphate form that mimics the natural building block adenosine. By incorporating into the viral rna chain it prevents further elongation of the viral genome. This inhibition reduces the amount of virus produced in infected cells. The pharmacokinetics of Videx EC involve slower gastrointestinal absorption compared to immediate-release didanosine. Its chemical structure includes a phosphoramidate pro-drug that improves oral bioavailability. The intended therapeutic effect is to suppress hiv replication and slow disease progression in patients.

Videx EC may cause peripheral neuropathy which can manifest as tingling or numbness in the extremities. Patients may also experience pancreatitis presenting as severe abdominal pain and nausea. Hepatic function alterations such as elevated liver enzymes have been reported in some individuals. Occasional bone marrow suppression can lead to anemia or reduced white blood cell counts. Gastrointestinal disturbances including nausea diarrhea or abdominal discomfort are common. In rare cases immune mediated reactions such as guillain barre syndrome have been observed. Long term use may be associated with mitochondrial toxicity contributing to muscle weakness fatigue.

Videx EC may cause nausea or loss of appetite in some patients. It can lead to mild skin rash in certain individuals. Occasionally it might result in headaches or dizziness. Some people experience changes in taste sensation. The medication can occasionally affect liver function leading to elevated enzymes. Hypersensitivity reactions such as itching may occur. Fatigue is reported by a small percentage of users. Persistent dry cough has been observed in rare cases.